Dalton Venture

Dalton Venture is a Chinese venture capital firm specializing in early-stage investments within the healthcare and technology sectors. The firm is headquartered in Shanghai, with additional offices in Shenzhen and Hong Kong. Dalton Venture has a strong focus on medical services and innovative medical technologies, including medical AI, women's and children's health, high-end medical devices, and gene and cell therapy.

The firm's investment strategy emphasizes partnering with entrepreneurs who demonstrate continuous innovation capabilities and a keen understanding of social change. Dalton Venture aims to create unicorns by nurturing entrepreneurs with shared values and vision. The firm has extensive experience in incubating early-stage companies and managing billion-dollar listed companies, leveraging deep industry experience and resources to provide strong investment support and create high-value returns for partners.

In April 2025, Dalton Venture expanded its operations to Hong Kong, targeting new investments in the life sciences sector. The firm applied for an asset-management license in Hong Kong and expects to start pursuing investments after receiving government approval. This expansion reflects Dalton Venture's commitment to leveraging Hong Kong as a springboard for global clinical development, regulatory pathways, and international fundraising, aiming to empower entrepreneurs and accelerate the globalization of life sciences innovation.